NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) reported Q1 Revenue for the quarter came in at $3.04 million versus the consensus estimate of $1.18 million.

For earnings history and earnings-related data on NewAmsterdam Pharma Company N.V. (NAMS) click here.